List of Monoferric drug patents

Monoferric is owned by Pharmacosmos As.

Monoferric contains Ferric Derisomaltose.

Monoferric has a total of 2 drug patents out of which 0 drug patents have expired.

Monoferric was authorised for market use on 16 January, 2020.

Monoferric is available in solution;intravenous dosage forms.

Monoferric can be used as method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney disease, by administering ferric derisomaltose.

The generics of Monoferric are possible to be released after 14 August, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10414831 PHARMACOSMOS AS Stable iron oligosaccharide compound
Mar, 2029

(5 years from now)

US8815301 PHARMACOSMOS AS Stable iron oligosaccharide compound
Aug, 2029

(6 years from now)

Drugs and Companies using FERRIC DERISOMALTOSE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: Method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney d...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

MONOFERRIC family patents

8

United States

3

Denmark

3

China

3

European Union

2

Slovenia

2

Lithuania

2

Hungary

2

Croatia

2

Portugal

2

Spain

2

Poland

2

RS

1

South Africa

1

Mexico

1

Australia

1

Hong Kong

1

Philippines

1

Brazil

1

Cyprus

1

Korea, Republic of

1

Ukraine

1

Japan

EA

1

EA

1

Canada

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in